Connect with us

News

Fairtility launches AI Academy to demystify use of AI in fertility care

The sessions will be taught by experts in AI, fertility, clinical research, digital health and patient care

Published

on

Fairtility has launched a new educational platform to highlight the importance of AI in fertility care. 

The AI Academy was officially announced at this month’s European Society of Human Reproduction and Embryology (ESHRE) annual meeting in Milan.

Dr Gerard Letterie, a reproductive endocrinology expert and infertility specialist at Seattle Fertility, serves as the Academic Head of the AI Academy.

He has introduced the first AI Academy session, followed by a panel discussion with four of the most recognised authorities in the field of IVF.

“At ESHRE, we confirmed our understanding of the state of AI in IVF,” says Dr Letterie. “The field is evolving and maturing rapidly and the uptake of these tools hinges on education and understanding.

“The industry knows that AI presents an important opportunity in fertility care, but does not fully understand what capabilities and limitations exist, nor what to expect out of AI in this field. Our goal with the AI Academy is to provide the needed education, bringing IVF professionals into the conversation on AI transformation for fertility care.”

The infertility specialist adds: “IVF professionals will develop a deeper understanding of this technology and how it can serve them in their work, and ultimately, improve IVF outcomes for prospective parents. I am honoured to head the AI Academy with the support of Fairtility.”

Eran Eshed, CEO and co-founder of Fairtility, says that investing in education for IVF professionals will help them better understand the potential for AI to transform the IVF industry. “We believe that knowledge is the best tool to resolve concerns of the unknown and help usher in the capabilities of AI to advance the efficacy of IVF treatment.

“We are building a community of experts and creating a space for dialogue, the sharing of ideas, innovation and productive argumentation – all in an effort to advance our industry to its fullest potential.”

The AI Academy will host a roster of speakers covering a range of topics from the basics of AI, AI and the IVF lab, AI in clinical and management, as well as ethics and best practices in AI’s application.

The first AI Academy session called, “AI, the new frontier: Everything you need to know about this tech” will take place on September 2 and will be led by Dr Nadav Rapoport of Ben Gurion University’s department of software and information systems engineering.

“We see expanding interest as AI technology for IVF continues to advance, yet there are no definable parameters or baselines for AI’s adoption in this industry,” Eshed adds.

“Our AI Academy is poised to centre the pendulum on AI by establishing a coherent, organised field that provides accessible education and conversation, bringing early and late adopters together to shorten the innovation adoption cycle for AI in fertility care.”

The Israeli software company aims to maximise IVF outcomes by using AI and computer vision algorithms to analyse morphological and morphokinetic features and provide early, data-driven embryo quality.

For more info, visit fairtility.com/AIAcademy.

Hormonal health

Medichecks acquires My Menopause Centre to expand specialist hormone health services

Published

on

Digital diagnostics company Medichecks has acquired specialist menopause health platform and clinic My Menopause Centre.

The deal is part of Medichecks’ move into clinical services and follows its earlier purchase of Leger Clinic, creating what the company describes as a hormone health offering for women and men across the UK.

Medichecks and My Menopause Centre will combine digital services with clinical governance. The acquisition aims to enhance Medichecks’ ability to deliver integrated testing, diagnosis and ongoing clinical support.

The combined group plans to grow its specialist hormone health services, supporting patients across the UK with clinical care throughout different stages of their hormone health journey.

Helen Marsden, co-founder of Medichecks, said: “At Medichecks, our mission is to make healthcare more accessible, evidence-based and patient-centred.

“Helen and Clare have built an outstanding, clinically credible platform that is transforming menopause care for women across the UK.

“Medichecks now owns two CQC Outstanding-rated clinics, the only clinics in their respective sectors to achieve this rating, and we are deeply committed to delivering safe, compassionate and patient-centric care.

“We’re proud to continue the founders’ legacy while supporting the next stage of growth, ensuring more women can access high-quality menopause care when they need it most.”

The CQC, or Care Quality Commission, is the independent regulator of health and social care in England.

The acquisition supports Medichecks’ plans to make hormone healthcare more accessible by delivering integrated testing, diagnosis and ongoing clinical support for patients across the UK.

Helen Normoyle, co-founder and chief executive of My Menopause Centre, said: “We set out to build something resilient, clinically credible and scalable, not just fast.

“Our mission has always been to make menopause care compassionate, accessible and grounded in evidence. Medichecks shares that vision.

“Their digital platform, commitment to clinical excellence and patient-centred care make them the ideal partner to take My Menopause Centre into its next chapter.

“This milestone reflects not only a strong product, but a remarkable team and community.

“I’m deeply proud of what we’ve built and excited to see My Menopause Centre grow further under Medichecks’ leadership.”

Continue Reading

Menopause

Menopause specialist Haver joins Midi Health

Published

on

Menopause specialist Dr Mary Claire Haver has been appointed as the first chief agewell officer at virtual care clinic Midi Health.

In the role, Dr Haver will work with Midi’s clinical team to develop the AgeWell platform, described as a proactive health model that integrates perimenopause and menopausal care with metabolic health, bone density, brain health and cardiovascular risk assessment.

The platform aims to provide preventative care targeting what the company describes as the primary drivers of female mortality and disability: heart disease, bone loss and cognitive decline.

Joanna Strober, chief executive and co-founder of Midi Health, said: “Longevity care has historically ignored women’s biology, especially during the critical windows of midlife and menopause.

“At Midi Health, we are committed to extending healthspan, not just lifespan, and making that care accessible to millions of women as a core pillar of their health.

“By collaborating with Dr Haver, we are ensuring women continue to have access to care designed for their bodies, their hormones, and their real lives.”

Dr Haver is board-certified in obstetrics and gynaecology, a Menopause Society certified practitioner, a certified culinary medicine specialist and an adjunct associate professor of obstetrics and gynaecology at The University of Texas Medical Branch.

After a career in academic medicine, Dr Haver founded The Pause Life, described as a science and education-based resource for women navigating perimenopause and the menopause transition.

Through her books, unPaused podcast and digital platform, she has provided education on midlife health.

Dr Mary Claire Haver said: “I have spent my career advocating for women to receive the science-backed, no-nonsense guidance they deserve.

“I chose to partner with Midi Health because they are the only platform with the scale and medical rigour to deliver the kind of care women deserve, regardless of their zip codes.

“Together, we are setting a new standard for proactive, preventative care that meaningfully extends both lifespan and healthspan for women.”

Continue Reading

Entrepreneur

Kate Ryder headlines Women’s Health Week USA 2026 as full agenda goes live

Published

on

Women’s Health Week USA 2026 has unveiled its first populated agenda, anchored by an opening keynote from Kate Ryder, Founder and CEO of Maven Clinic, and featuring a cross-sector lineup shaping the next phase of scale in women’s health.

You can view the full agenda here.

Taking place May 13–14, 2026, at the New York Academy of Medicine, Women’s Health Week USA brings together the full women’s health ecosystem to focus on one central question: what does it take to move women’s health from innovation to institutional scale?

Kate Ryder will open Day 1 with a keynote drawing on her experience building Maven Clinic into the world’s largest virtual clinic for women’s and family health.

Under her leadership, Maven has partnered with employers and health plans to deliver care across fertility, maternity, postpartum, paediatrics, and menopause at scale.

Her perspective sets the tone for a program centered on commercialisation, partnership, and sustainable growth.

Beyond the opening keynote, the newly released agenda reflects the sector’s growing maturity.

Across two days, the program features 70+ speakers, with representation from leading organizations including the FDA, Planned Parenthood, CVS Health Ventures, Samsung Next, NIH, WHO, and Maven Clinic.

Sessions span investment and deal flow, clinical innovation, regulation, data and technology, and market expansion, alongside dedicated pitch sessions and curated 1:1 matchmaking designed to turn insight into action.

The agenda has been built to facilitate meaningful connections across the ecosystem, with partnerships positioned as the primary driver of scale.

As women’s health continues to attract institutional capital and global attention, Women’s Health Week USA 2026 offers a clear snapshot of where the market is heading, and who is shaping it.

The full agenda is now live, with additional speakers and partners to be announced in the coming months.

View the full programme here.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.